Using Disease Management and Market Reforms to Address the Adverse Economic Effects of Drug Budgets and Price and Reimbursement Regulations in Germany
Tim Schwermann(Leibniz University Hannover), J.‐Matthias Graf v. d. Schulenburg(Hanover College), Wolfgang Greiner(Bielefeld University)
Cited by 21
Related Papers
Barriers and Strategies in Guideline Implementation—A Scoping Review
|Healthcare|2016|946
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903
German Value Set for the EQ-5D-5L
|PharmacoEconomics|2018|618
Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study
|Quality of Life Research|2010|476
A single European currency for EQ-5D health states
|The European Journal of Health Economics|2003|465